1. The Path to Intravitreal Bevacizumab. https://retinatoday.com/articles/2009-may-june/0609_05-php. Accessed 15 Nov 2021.
2. LUCENTIS (ranibizumab injection) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf. Accessed 15 Nov 2021.
3. Eylea (aflibercept injection) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf. Accessed 15 Nov 2021.
4. Drug Approval Package: BEOVU (brolucizumab-dbll). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761125_Orig1_toc.cfm. Accessed 15 Nov 2021.
5. Rosenfeld PJ, Windsor MA, Feuer WJ, Sun SJJ, Frick KD, Swanson EA, et al. Estimating medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration. Am J Ophthalmol. 2018;191:135–9.